Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061001 | 0.88 | KMT2A (0.50) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL6293263 | 0.87 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL437697 | 0.87 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL30071070 | 0.86 | KMT2A (0.48) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL20154238 | 0.86 | KMT2A (0.48) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL17128365 | 0.86 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL20702366 | 0.85 | KMT2A (0.47) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL19021085 | 0.83 | MEN1 (0.69) | KMT2AMEN1KDM4EMAPTALDH1A1 | |
| SCHEMBL7369890 | 0.82 | NUDT1 (0.52) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL29643272 | 0.78 | KMT2A (0.44) | KMT2AMEN1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505545-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-22 | — | — | US | disclosed |
| CN-109890793-B | Novel anthelmintic quinoline-3-carboxamide derivatives | 拜耳动物保健有限责任公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-3538512-B1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538512-B1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| US-20210115026-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-20210115026-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| EP-3538512-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087036-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087036-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505545-B2 | Anthelmintic quinoline-3-carboxamide derivatives | HRH4, HRH2, H1-5 | KMT2A 623/4885MEN1 1839/4885NPC1 2094/4885 |
| US-20210115026-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | HRH4, HRH2, HRH1 | KMT2A 621/4885MEN1 1936/4885NPC1 2081/4885 |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | HRH4, HRH2, H1-5 | KMT2A 569/4885MEN1 1693/4885NPC1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.